Clinical Trial Update: Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM [Phase 1]

View source ↗

Summary

A Phase I clinical trial update for CB-NK-TGF-ßR2-/NR3C1- therapy in recurrent gliosarcoma and recurrent supratentorial glioblastoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• CB-NK-TGF-ßR2-/NR3C1-

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma | Phase 1 | Status: RECRUITING